Jun 12 Watch 5:10 Why the AT&T mega-merger is a green light for other businesses AT&T can complete an $85 billion purchase of Time Warner, a federal judge ruled on Tuesday. Best known as a wireless provider, AT&T would acquire major content creators like HBO, CNN and Warner Brothers under the deal. The Justice Department… Continue watching
Dec 27 Column: The 10 most remarkable deals — and busts — of 2016 By Ben Gomes-Casseres This year saw another bumper crop of remarkable business deals. Even if the volume of mergers and acquisitions fell short of the 2015 record, new mergers and partnerships were formed, and some big ones were busted up. Continue reading
Jun 30 Column: What’s behind these big merger deal busts? By Ben Gomes-Casseres Anti-trust authorities have been active of late: several big merger deals have been stopped dead in their tracks. Continue reading
Apr 06 Watch 4:54 News Wrap: Pfizer, Allergan call off record merger By PBS News Hour In our news wrap Wednesday, pharmaceutical giant Pfizer and Irish rival Allergan abandoned a merger agreement after the Obama administration imposed rules to block the company from saving millions of dollars in taxes. Also, former coal executive Don Blankenship was… Continue watching
Dec 07 Clinton offers new ‘exit tax’ on U.S.-foreign company mergers By Lisa Lerer, Associated Press Hillary Clinton on Wednesday will unveil a proposal for a new "exit tax" aimed at cracking down on corporate inversions, a practice that permits U.S. companies to merge with corporations overseas to lower their tax bill. Continue reading
Oct 05 Column: Why mergers are booming By Ben Gomes-Casseres Another day, another merger. Telephone companies, drug companies, airlines, hospitals, retail stores and now beer. Why?… Continue reading
Aug 26 Watch How American companies change their address to avoid corporate taxes By PBS News Hour Continue watching
May 03 Watch Pfizer-AstraZeneca deal could impact drug development By PBS News Hour Pfizer made a $106 billion bid for the British drug maker AstraZeneca this week in a move that was potentially motivated by lower corporate tax rates overseas. The deal could also affect the development of new drugs. Hari Sreenivasan speaks… Continue watching